INSPECS GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.5 GBX | -0.88% |
|
-25.66% | -32.74% |
| Jun. 06 | Inspecs falls as interim revenue expected to fall annually | AN |
| Jun. 06 | TRAFIGURA PUBLISHES 2024 HALF YEAR RESULTS… | RE |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The stock, which is currently worth 2024 to 0.39 times its sales, is clearly overvalued in comparison with peers.
- The company has a low valuation given the cash flows generated by its activity.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -32.74% | 73.73M | C- | ||
| +24.59% | 45.32B | B | ||
| +0.30% | 18.79B | B- | ||
| -22.28% | 2.17B | D+ | ||
| +19.50% | 1.98B | C+ | ||
| +20.05% | 1.14B | - | ||
| -41.45% | 679M | - | ||
| -7.76% | 667M | - | ||
| -45.13% | 628M | B- | ||
| +56.94% | 605M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SPEC Stock
- Ratings INSPECS Group plc
